India Pharma Outlook Team | Wednesday, 12 November 2025
AstraZeneca’s Baxdrostat has achieved a major milestone in the treatment of resistant hypertension (rHTN).
Phase III trials demonstrate very large and long-term improvements in blood-pressure. The drug blocks the hormone aldosterone by inhibiting the aldosterone synthase selectively.
The studies of both BaxHTN and Bax24 established a good and positive safety profile. Baxdrostat achieved its major endpoints in these landmark trials with statistically significant and clinically meaningful reductions in seated and 24-hour ambulatory blood pressure compared to placebo. Baxdrostat patients had significant systolic blood pressure (SBP) improvements and they can transform the hypertension treatment.
Also Read: India's Path to Billion-Dollar Drugs: Building a Strong Ecosystem
Bryan Williams, Chair of Medicine at University College London, primary investigator, said: “The landmark results from Bax24 Phase III trial demonstrate that patients with the hardest-to-control hypertension treated with baxdrostat achieved a highly clinically meaningful 14 mmHg placebo-adjusted reduction in 24-hour systolic blood pressure, which could transform treatment practice."
"It's remarkable to see this magnitude of reduction coupled with the fact that just over 70% of baxdrostat patients achieved guideline targets, consistently over 24 hours.”
Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, said: “The Bax24 data demonstrate the significant impact that baxdrostat’s long half-life and highly selective inhibition of aldosterone synthase can have in improving 24-hour and overnight blood pressure for patients with resistant hypertension."
The results position Baxdrostat as a potential game-changer for millions of patients whose hypertension remains uncontrolled despite current therapies.
